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Abstract
As WHO recommends vitamin A supplementation (VAS) at vaccination contacts after age 6 months, many children receive VAS together
with measles vaccine (MV). We aimed to investigate the immunological effect of VAS given with MV. Within a randomised placebo-controlled
trial investigating the effect on overall mortality of providing VAS with vaccines in Guinea-Bissau, we conducted an immunological sub-study
of VAS v. placebo with MV, analysing leucocyte counts, whole blood in vitro cytokine production, vitamin A status and concentration
of C-reactive protein (CRP). VAS compared with placebo was associated with an increased frequency of CRP≥5mg/l (28 v. 12 %; P= 0·005).
Six weeks after supplementation, VAS had signiﬁcant sex-differential effects on leucocyte, lymphocyte, monocyte and basophil cell
counts, decreasing them in males but increasing them in females. Mainly in females, the effect of VAS on cytokine responses differed
by previous VAS: in previous VAS recipients, VAS increased the pro-inﬂammatory and T helper cell type 1 (Th1) cytokine responses, whereas
VAS decreased these responses in previously unsupplemented children. In previous VAS recipients, VAS was associated with increased IFN-γ
responses to phytohaemagglutinin in females (geometric mean ratio (GMR): 3·97; 95 % CI 1·44, 10·90) but not in males (GMR 0·44; 95 % CI
0·14, 1·42); the opposite was observed in previously unsupplemented children. Our results corroborate that VAS provided with MV has
immunological effects, which may depend on sex and previous VAS. VAS may increase the number of leucocytes, but also repress both the
innate and lymphocyte-derived cytokine responses in females, whereas this repression may be opposite if the females have previously
received VAS.
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Vitamin A is important for fundamental immunological
functions, including modulation of differentiation, maturation,
migration or activation of dendritic cells, T cells and NK cells(1).
The WHO estimates that 190 million children under the age
of 5 years worldwide are at risk of vitamin A deﬁciency (VAD),
especially in Africa and South East Asia(2). To alleviate and
prevent VAD, the WHO recommends high-dose vitamin A
supplementation (VAS) at routine vaccination contacts after
6 months of age(3). According to the current vaccination
schedule, the ﬁrst vaccine to be given after the age of 6 months
is the measles vaccine (MV) scheduled at age 9 months(4).
Vaccines may have effects on overall mortality and morbidity
beyond the speciﬁc protection against the targeted disease – the
so-called non-speciﬁc effects(5). Many studies have shown that
live attenuated MV has beneﬁcial effects on mortality far
exceeding what can be ascribed to the prevention of measles
cases, presumably due to immune-modulating effects, leading
to increased resistance towards unrelated infections(5–7).
* Corresponding author: K. J. Jensen, email kjj@ssi.dk
† Data and study protocol are available upon request to the corresponding author.
Abbreviations: CRP, C-reactive protein; GMR, geometric mean ratio; MV, measles vaccine; PHA, phytohaemagglutinin; PR, proportion ratio; RBP, retinol-binding
protein; VAD, vitamin A deﬁciency; VAS, vitamin A supplementation.
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Several studies have suggested that high-dose VAS and
vaccines interact with effects on overall mortality and morbidity.
Our group has previously found that VAS together with MV
increases the MV-speciﬁc antibody response(8,9). We have
hypothesised that VAS may enhance both the measles-speciﬁc
and the non-speciﬁc effects of MV via beneﬁcial general
immune-stimulating effects(10).
In Guinea-Bissau, from 2007 to 2011, before the imple-
mentation of the WHO policy of giving VAS at vaccination
contacts, we conducted a randomised placebo-controlled trial
to evaluate the effect of this recommendation. At vaccination
contacts after 6 months of age, children were randomised to
VAS or placebo, the main outcomes being all-cause child
mortality and morbidity.
Nested within the trial, we performed a sub-study to
investigate the effects of VAS together with MV on non-measles-
speciﬁc immunological outcomes. At baseline and 6 weeks after
randomisation, we measured vitamin A levels, C-reactive
protein (CRP) levels, differential counts and in vitro cytokine
production to allow simultaneous evaluation of the effect of
VAS on different parts of the immune system.
Prompted by previous studies showing that the effect of VAS
on morbidity or mortality depends on sex(11,12), season of
supplementation(13) or previous high-dose VAS(14), we
pre-speciﬁed to investigate the possible interactions between
VAS, sex, season of supplementation and previous VAS.
Indeed, the main trial corroborated that there are important
interactions: there was no overall mortality effect of VAS, but
the effect was sex-differential, with VAS being beneﬁcial for
females but detrimental for males. These sex-differential effects
were most evident in the dry season and in children who had
previously received VAS(15).
Methods
The present immunological sub-study was nested within a
randomised trial of administering VAS v. placebo together with
routine vaccinations in Guinea-Bissau, described in detail
elsewhere(15).
Main trial
Between August 2007 and November 2010, children aged
between 6 and 23 months were invited to participate in the
main trial when they came to the healthcare centres for routine
vaccination. A study nurse inspected the vaccination cards and
identiﬁed eligible children. VAS within the preceding month
was an exclusion criterion. If parents provided oral and
written consent, the children were randomised to vitamin A or
placebo groups. Randomisation was stratiﬁed by child sex.
Mothers drew a lot from an envelope containing twenty lots; ten
for each treatment arm. The number on the lot indicated from
which of the two numbered bottles the children would receive
an oral supplement. Children under the age of 1 year received
0·5 ml; children who had reached 1 year of age received 1ml.
For the children in the VAS group, this meant that they received
100 000/200 000 IU vitamin A (retinyl palmitate) dissolved in
vegetable oil with vitamin E added as an antioxidant (40 IU/ml).
Children in the placebo group received the same amount of oil
with vitamin E. MV was supplied by UNICEF(15). National VAS
campaigns were conducted by the Ministry of Health approxi-
mately every 6 months. One month before the announced date
of a campaign, inclusion into the main trial was paused in order
to prevent children from receiving two doses of VAS within a
month(16). In the month following a campaign, we included
only children who had not received VAS in the campaign.
The immunological sub-study
Between September 2007 and June 2009, children who were
due to receive MV were additionally invited to participate in the
immunological sub-study. The mothers were explained that
participation was voluntary and that participation in the main
study was not contingent upon enrolment in the sub-study. Oral
and written consent was obtained separately for the sub-study.
With consent, a blood sample was obtained before rando-
misation in the main trial to vitamin A or placebo. All children
from whom we had obtained a blood sample at inclusion were
visited by a ﬁeld assistant 6 weeks after inclusion and were
asked to visit the healthcare centres for the follow-up blood
sample collection. If the child could not be found at home, the
assistant kept revisiting the home until 100 d had passed since
inclusion; the child was then registered as lost to follow-up.
Blood sampling procedures and analyses
Before blood sampling, axillary temperature, weight and
mid-upper arm circumference (MUAC) were measured, and the
mother was interviewed about the health of the child, including
symptoms of disease on the day of blood draw and use of
medicines during the 3 d before blood draw. Venous blood was
drawn into a heparinised tube and an EDTA tube. The EDTA
tubes were kept in a cool box until arrival at the laboratory
where they were left at ambient temperature to acclimatise
before measurement. The heparinised blood was maintained at
ambient temperature. A thick and thin blood slide was prepared
for examination of malaria. The slides were Giemsa-stained and
microscopically examined for malaria parasites by an experi-
enced laboratory technician. All mothers were informed of the
results of the malaria slide by a visiting ﬁeld assistant on the
following day. None of the children had positive malaria slides.
Leucocyte counts
Automated differential counts were performed on blood
collected in EDTA tubes using an ABX pentra 60 (HORIBA
ABX). The accuracy and precision of measurements were
validated at regular intervals using a commercial standard
preparation (ABX Difftrol; HORIBA ABX). After the analyses,
the EDTA tubes were centrifuged to separate plasma.
Retinol-binding protein and C-reactive protein
Plasma was analysed for retinol-binding protein (RBP) and CRP.
RBP and CRP were analysed using sandwich ELISA as described
elsewhere(17), except that the poly-clonal chicken anti-human
RBP secondary antibody was from Immunology Consultants
Laboratory (cat. no: CRBP-80P-Z). Before measurements, we
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validated the performance of the antibody against the originally
used antibody in collaboration with the developer of the assay
(Jürgen Erhardt). Samples were measured in duplicate and
re-measured if the CV between duplicates was above 20 % for
RBP and above 20 % for samples with a mean value between
3 and 7 mg/l for CRP.
Whole blood stimulation assay
The heparinised blood was maintained at ambient temperature
but shielded from direct sunlight until processing. The blood
was diluted 1:10 with RPMI-1640 medium without glutamine
with added streptomycin (100 μg/ml), penicillin A (100 IU/ml),
glutamate (2 mM) and pyruvate (1 mM) (all from Invitrogen).
Stimulations were performed in sterile multiwell plates
(Nunclon U-shape; NUNC) in a ﬁnal volume of 200 µl using
phytohaemagglutinin (PHA, 2 μg/ml; Wellcome Diagnostics),
Lipopolysaccharide (LPS, 1 ng/ml; Sigma-Aldrich Chemie),
Polyinosine-polycytidylic acid (Poly I:C, 10 µg/ml; InvivoGen),
palmitoyl(3)-cysteine-serine-lysine(4) (Pam3cys, 100 ng/ml;
InvivoGen), puriﬁed protein derivative of Mycobacterium
tuberculosis (PPD, 10 μg/ml; Statens Serum Institut), tetanus
toxoid (TT, 1·5 Lf/ml; Statens Serum Institut), Bacille Calmette-
Guérin vaccine (BCG, 1:1000 of vaccine preparation; Statens
Serum Institut), oral polio vaccine (OPV, 1:100 dilution of
vaccine preparation; GlaxoSmithKline Biologicals) and diph-
theria toxoid (DT, 1 Lf/ml; Statens Serum Institut). Medium
alone samples (medium) were included as well. Culture plates
were incubated at 37°C/5 % CO2/100 % humidity. Supernatants
were collected on day 1 (medium1, LPS and Pam3cys) or on
day 3 (medium3, PHA, Poly I:C, BCG, PPD, OPV, TT and DT)
and maintained below −40°C until analysis. Each culture well
was visually assessed upon harvest for signs of contamination.
Supernatant concentrations (the lower limit of detection
(LLD) of the assay in pg/ml is given in parenthesis) of IL-2 (6),
IL-10 (5), IL-5 (3), IFN-γ (5) and TNF-α (10) were measured
simultaneously using a Luminex cytokine kit (Luminex
Corporation) and a buffer reagent kit (BioSource) on a
Luminex-100 cytometer (Luminex Corporation), equipped with
STarStation software (Applied Cytometry Systems). The samples
were tested in a random order (VAS and placebo mixed), but
with paired baseline and follow-up samples from one subject in
the same assay.
Sample size considerations
In previous studies utilising a similar setup, we had observed
signiﬁcant differences in cytokine production using samples
sizes of approximately 200 children in each group in a
cross-sectional design. In the present study, we included
baseline samples to reduce the intra-individual noise and the
necessary sample size accordingly. With an expected 20% loss to
follow-up, we aimed to include 125 children per group – that is,
100 children per group for the ﬁnal analyses.
Statistical analysis
Analyses were performed using Stata 12 (StataCorp LP).
Cytokine data were log transformed. For several of the cytokine
outcomes, a proportion of the measurements was below the
LLD of the assay, deﬁned by the manufacturer (see above), and
denoted here as non-detectable (ND) measurements. ND
measurements were handled by multiple imputations based on
Tobit regression(18,19). The parameters of the underlying normal
distribution are estimated by Tobit regression and values below
the detection limit are drawn multiple times from a truncated
normal distribution. The imputations incorporate the correlation
between baseline and follow-up samples. Geometric mean
ratios (GMR) were obtained as anti-logged coefﬁcients. For
distributions with >50 % ND measurements, the proportion of
detectable samples was analysed by Poisson regression giving
proportion ratios (PR).
Where all the measurements in a subgroup analysis were
below LLD in either of the randomisation groups, Poisson
regression was not possible, and CI were obtained using
proﬁle-log-likelihood estimation(20).
For distributions with <50 % ND measurements, the ratios of
IFN-γ:IL-5 and TNF-α:IL-10 responses were analysed as crude
markers of the balance of Th1 v. Th2 cytokine responses and
the pro- v. anti-inﬂammatory cytokine responses, respectively;
we report GMR ratios.
To test the effect of VAS on overall cytokine responsiveness,
irrespective of stimulation, a collective test for each cytokine was
performed, including all conditions and adjusting for the main
effect of stimulation. This, however, was only done if the test of
homogeneity for the BCG effect across the different stimulations
was non-signiﬁcant (test of homogeneity: P>0·05) in the particular
analysis, indicating that the stimulations could be merged.
Blood cell counts were analysed by linear regression on the
log-transformed values, anti-logging estimates to present GMR,
with CI obtained by bootstrap. Plasma levels of CRP were
analysed as the frequency of individuals having a measurement
≥5 mg/l using Poisson regression with robust standard errors
providing PR. RBP was analysed with linear regression giving a
numerical difference of the mean between VAS and placebo;
prevalence of VAD (RBP<0·83 µmol/l(21)) was analysed with
Poisson regression giving PR.
Estimates were reported with 95 % CI. A GMR or PR>1 can
be interpreted as an increasing effect of VAS, whereas a GMR or
PR<1 represents a decreasing effect of VAS.
All analyses were adjusted for baseline levels and sex, as the
initial randomisation was performed by sex. Children who had
previously received VAS were slightly older than children not
previously supplemented (data not shown). Adjusting for age in
the analysis of the VAS effect stratiﬁed by previous VAS did not
affect the VAS estimates (data not shown).
The estimates of the effect of VAS were stratiﬁed by sex,
season of supplementation (rainy v. dry season) and previous
VAS (yes or no); the stratiﬁcation by previous VAS was further
substratiﬁed by sex, as the effect modiﬁcation had previously
been found to be sex speciﬁc(14).
We have corrected all estimates for multiple comparisons,
separately for cytokines, leucocyte counts and CRP/RBP, using
Simes false discovery rate procedure(22,23). The statistical tests in
the text are presented, both adjusted and unadjusted, whereas
estimates in tables are highlighted only if signiﬁcance was main-
tained after adjustment; P values in the ﬁgures are unadjusted.
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Ethical considerations
The trial including the immunological sub-study was conducted
according to the guidelines laid down in the Declaration of
Helsinki, and all procedures were approved by the Ministry of
Health’s Committee on Research Coordination in Guinea-Bissau
and by the Danish Central Ethical Committee. The trial was
registered at clinicaltrials.gov (no. NCT00514891).
Results
We included 280 children, of which 258 had a blood sample
taken at inclusion. At follow-up, 146 blood samples were
successfully obtained and analysed (Fig. 1), giving a loss to
follow-up of 43 %, evenly distributed between VAS and placebo
arms. Of the 146 children, seventy-three had differential
counts performed, 134 had RBP and CRP measured and 120
had cytokines measured. Overall, children with a successful
laboratory analysis were not notably different from the children
lost to follow-up with respect to background parameters,
except for a larger frequency of lost males (61 % lost v. 45 %
followed-up) (online Supplementary Table S1). Among the
analysed infants, the VAS and placebo arms were comparable
with respect to background characteristics, with few exceptions:
among females, children in the placebo arm were slightly taller
at enrolment and their mothers were older and had larger
MUAC, whereas among males fewer children in the placebo
group had received OPV at birth and more had maternally
reported cold (Table 1). Adjustment for these factors did not
affect the estimates of VAS (data now shown).
Effect of vitamin A supplementation on vitamin A status
and inﬂammation at follow-up
At baseline and follow-up, 70 and 72%, respectively, were VAD
(RBP<0·83 µmol/l(21)); 19 % had CRP≥5mg/l and 14% had
CRP≥10mg/l. VAS had no effect on levels of plasma RBP or on
the frequency of VAD, overall or by sex (Table 2), and this
was unaffected by vitamin A status at baseline, or by elevated
CRP (≥5mg/l) at follow-up (data not shown). Compared with
placebo, VAS signiﬁcantly increased the risk of elevated CRP
(≥5mg/l) (VAS: 28% v. placebo: 12%, PR: 3·15 (95% CI 1·49,
6·63), adjusted for multiple comparisons P= 0·005) (Table 2). The
same conclusion was reached using a cut-off of 10mg/l (data not
shown). Sex (Table 2), season of supplementation and previous
VAS (data not shown) did not signiﬁcantly modify this effect.
Effect of vitamin A supplementation on leucocyte count values
Overall, there was no effect of VAS on leucocyte counts
(Table 2). There was a signiﬁcant interaction between VAS
and sex for several subsets. In males, VAS was associated with
signiﬁcantly lower counts of total leucocytes, lymphocytes
and monocytes, whereas the effect tended to be opposite in
females (interaction between sex and VAS adjusted for multiple
comparisons P= 0·01, P= 0·04, P= 0·03, respectively). The same
VAS PlaceboAgreed to enter main trial155/151
Refused participation in 
immunological study
16
No sample obtained
12
Moved: 3
Refused: 11
Unable to find home: 5
Dead: 0
Repeated no-shows: 5
Travelling: 8
Child sick: 3
Received VAS in campaign: 10
Unaccounted for: 0
No sample obtained at follow-up
1
Received VAS in campaign
before follow-up
1
No valid measurement at follow-up
or baseline
6
Agreed to enter immunological study
135
Agreed to enter immunological study
145
Refused participation in
immunological study
10
Blood sample obtained at baseline
123
In vitro assay: 114
Plasma for RBP/CRP: 118
Cell counts: 88
Agreed to bleed at follow-up
78
Blood sample obtained at follow-up
77
Valid measurement at follow-up
and baseline
70 (48 %)
In vitro assay: 57 (39 %)
RBP/CRP: 65 (45 %)
Cell counts: 35 (24 %)
Valid measurement at follow-up
and baseline
76 (52 %)
In vitro assay: 63 (43 %)
RBP/CRP: 69 (47 %)
Cell counts: 38 (26 %)
Blood sample obtained at follow-up
81
Agreed to bleed at follow-up
84
Blood sample obtained at baseline
135
In vitro assay: 123
Plasma RBP/CRP: 130
Cell counts: 90
No sample obtained
10
Moved: 3
Refused: 13
Unable to find home: 6
Dead: 1
Repeated no-shows: 4
Travelling: 10
Child sick: 3
Received VAS in campaign: 8
Unaccounted for: 3
No sample obtained at follow-up
3
Received VAS in campaign
before follow-up
1
No valid measurement at follow-up
or baseline
4
Fig. 1. Flow chart. Percentages are the fraction of total enrolled infants (n 146). VAS, vitamin A supplementation; RBP, retinol-binding protein; CRP, C-reactive protein.
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pattern was observed for basophils (adjusted P= 0·01) (Fig. 2(a)
and Table 2). Season did not modify the effect of VAS (data
not shown). The sex-differential effects for total leucocytes,
lymphocytes, monocytes and basophils were stronger in
children not previously supplemented compared with those
previously supplemented due to a stronger increasing effect
of VAS among previously unsupplemented females than
among previously supplemented females (online Supplementary
Table S2).
Effect of vitamin A supplementation on in vitro cytokine
production, overall and by sex
Overall, no cytokine outcomes were associated with VAS after
adjustment for multiple comparisons (online Supplementary
Table S3). The effect of VAS did not depend on vitamin A status
at baseline (data not shown).
There was no interaction between VAS and sex for any of
the cytokine responses (Fig. 2(b)–(f)), or between VAS and
season, when adjusted for multiple comparisons (data not
shown).
Effect of vitamin A supplementation on in vitro cytokine
production, by previous vitamin A supplementation, overall
and by sex
VAS was differentially associated with several cytokine
responses in children with previous VAS compared with no
previous VAS (Fig. 3). For children without previous VAS, VAS
was associated with a tendency towards reduced TNF-α
Table 1. Background characteristics at baseline*
(Percentages and numbers; medians and 10–90th percentiles; mean values and standard deviations)
Male Female
VAS Placebo VAS Placebo
Observations Observations
Background parameters %† n %† n P %† n %† n P
General All 31 35 39 41
Age (d) 0:09 0:17
Median 293 292 288 294
10–90 percentile 278–364 276–384 276–346 278–375
Dry season 45 14 49 17 0:78 56 22 44 18 0:26
Maternal and Age of mother (years) 0:27 0·005
socio-economic Median 27 24 23 27
10–90 percentile 19–36 17–34 18–33 20–38
Schooling of mother (years) 0:62 0:19
Median 6 7 7 5
10–90 percentile 0–11 0–10 0–11 0–11
MUAC of mother (mm) 0:27 0·001
Median 266 277 270 288
10–90 percentile 234–332 240–328 240–300 254–344
Electricity at home 23 7 21 7 0:90 50 18 30 12 0:08
Toilet inside 10 3 12 4 0:75 25 9 10 4 0:08
Anthropometry and
health at baseline
Polio vaccine at birth 84 26 57 20 0:02 77 30 71 29 0:53
Previous VAS 58 18 60 21 0:87 69 27 68 28 0:93
MUAC child (mm) 0:32 0:32
Mean 147 150 147 149
SD 11 13 11 10
Weight (kg) 0:31 0:08
Mean 8·7 9·0 8·3 8·8
SD 1·2 1·1 1·0 1·3
Height (cm)‡ 0:98 0:03
Mean 73 73 71 72
SD 3 2 3 3
Axillary temperature >37°C 0 0 3 1 0:34 0 0 0 0 –
Medicine use on day of enrolment 3 1 9 3 0:36 3 1 5 2 0:60
Maternally reported symptoms
Cold (runny nose) 7 2 50 16 <0·001 39 12 27 10 0:31
Coughing 29 9 43 15 0:24 26 10 22 9 0:70
Diarrhoea 10 3 0 0 0:06 13 5 12 5 0:93
Fever 10 3 9 3 0:91 8 3 5 2 0:62
Vomiting 0 0 3 1 0·336 5 2 0 0 0:14
Any of the above symptoms 42 13 60 21 0:14 54 21 44 18 0:37
VAS, vitamin A supplementation; n, number of individuals; MUAC, mid-upper arm-circumference.
* Infants with a valid measurement of plasma biomarker, in vitro cytokines and/or differential counts at baseline and follow-up. Statistical test using χ2 test for categorical values;
Kruskal–Wallis test for non-normally distributed numerical values; Student’s t test for normally distributed numerical values.
† Percentage is calculated with respect to the total number of individuals with the relevant information available.
‡ Absolute difference between VAS and placebo among females: 1·5 cm.
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responses to all stimuli compared with placebo, whereas the
opposite tendency was observed in children who had received
VAS previously. The same pattern was also observed for IL-10
and IFN-γ responses. Consequently, the TNF-α:IL-10 ratio
tended to be down-regulated by VAS compared with placebo in
children not previously supplemented, with the opposite
tendency in children with previous VAS. A similar effect was
observed for the IFN-γ:IL-5 ratio (Fig. 3(g) and (h)).
VAS had opposite sex-differential effect directions for
responses to PHA in children with v. without previous VAS.
Among previously supplemented children, VAS tended to be
associated with increased IFN-γ responses to PHA in females
but decreased responses in males (interaction between VAS
and sex, adjusted P= 0·23). Among children without previous
VAS, VAS was associated with decreased IFN-γ responses in
females but increased responses in males (interaction between
VAS and sex, adjusted P= 0·13). This resulted in a signiﬁcant
three-way interaction between VAS, previous VAS and sex
(adjusted P= 0·0007) (Fig. 2(g) and online Supplementary
Table S4).
Discussion
VAS v. placebo given with MV from 9 months of age was
associated with a number of immunological effects. First, VAS
was associated with a higher proportion of children with
elevated plasma CRP levels at follow-up. Second, VAS was
associated with a decrease in concentrations of several blood
cell subsets in males but an increase in females. Third,
there was an interaction between VAS and previous VAS on
several cytokine responses: VAS decreased particularly
pro-inﬂammatory and Th1 responses in children who had not
previously received VAS with an opposite effect in previously
supplemented children, particularly so in females. Fourth, VAS
increased PHA responses in females who had previously
received VAS with an opposite effect in previously unsupple-
mented females; for males, this modulation of previous VAS on
the effect of VAS was in the opposite direction, especially
for the responses of typical lymphocyte-derived cytokines
(IL-2, IL-5, IFN-γ).
Strengths and weaknesses
To our knowledge, the present study is the ﬁrst randomised
study to investigate the general (non-speciﬁc) immunological
effects of VAS given with MV in a real-life setting, therefore
directly testing the immunological implication of this WHO
policy.
However, some limitations are noted. First, our loss to follow-
up was higher than anticipated; many mothers refused the
second blood sample. The loss to follow-up was equally dis-
tributed across the randomisation groups. Although more boys
than girls were lost to follow-up, the distribution of treatment
allocation among the lost was similar for boys and girls. Second,
the subgroup analyses were based on small numbers, as the
study was not originally designed to power the three-way
interactions by sex and previous VAS. These analyses, however,
were posteriorly indicated by the epidemiological study show-
ing three-way interactions with respect to the main mortality
outcome. Third, multiple testing increased the risk of chance
Table 2. The effect of vitamin A supplementation (VAS) on leucocyte counts and plasma biomarkers, overall and stratified by sex*
(Geometric means (GM) and interquartile ranges (IQR); GM ratios (GMR) and 95% confidence intervals; difference in means (diff.) and 95% confidence
intervals; proportion ratios (PR) and 95% confidence intervals)
Sex†
VAS‡ Placebo‡ Overall† Male Female
GM IQR GM IQR GMR 95% CI GMR 95% CI GMR 95% CI P §
(n 35) (n 38) (n 73) (n 39) (n 34)
Total leucocytes 10:3 8:4–12:7 10:2 8:5–11:8 0:96 0:84, 1:09 0·82|| 0:71, 0:95 1:14 0:92, 1:43 0·003||
Lymphocytes 5:5 4:3–7:0 5:5 3:8–7:3 0:91 0:80, 1:03 0·80|| 0:69, 0:93 1:05 0:85, 1:31 0·02||
Monocytes 1:8 1:3–2:3 1:8 1:3–2:3 0:99 0:85, 1:16 0:81 0:66, 1:00 1:24 0:93, 1:64 0·02||
Neutrophils 2:1 1:3–2:7 1:9 1:8–2:6 0:98 0:76, 1:25 0:87 0:65, 1:17 1:11 0:79, 1:57 0·38
Eosinophils 0:3 0:2–0:6 0:3 0:2–0:5 0:93 0:67, 1:28 0:91 0:58, 1:42 0:96 0:64, 1:42 0·86
Basophils 0:2 0:1–0:2 0:1 0:1–0:2 0:99 0:80, 1:24 0:75 0:53, 1:04 1:39 1:08, 1:79 0·004||
Mean IQR Mean IQR Diff. 95% CI Diff. 95% CI Diff. 95% CI P§
(n 65) (n 69) (n 134) (n 63) (n 71)
RBP (μmol/l) 0:70 0:57–0:87 0:73 0:58–0:88 –0:03 –0:10, 0:04 0:03 –0:07, 0:13 –0:09 –0:18, 0:01 0:09
Proportion Proportion PR 95% CI PR 95% CI PR 95% CI P§
RBP<0·83 μmol/l 0·72 0·72 1:00 0:81, 1:23 1:01 0:77, 1:32 1:00 0:72, 1:37 0:96
CRP≥5mg/l 0·28 0·12 3:15 1:49, 6:63 3·65|| 1:29, 10:33 2:79 1:03, 7:52 0:71
RBP, retinol-binding protein; CRP, C-reactive protein.
* Infants with a plasma RBP<0·83 μmol/l were defined as vitamin A deficient.
† GMR or diff or PR with 95% CI comparing infants receiving VAS with infants receiving placebo. A GMR>1 can be interpreted as an increasing effect of VAS on the cell count.
‡ GM with IQR of leucocyte counts, or means and IQR for RBP levels, or proportion of individuals with RBP<0·83 µmol/l, or proportion of individuals with CRP≥5mg/l at follow-up
for the placebo group and the VAS group, respectively. GM presented as 106 cells/ml for all cell values.
§ Statistical test for interaction between VAS and sex.
|| Estimates and interaction P values that are still significant after adjustment for multiple comparisons.
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ﬁnding. We have therefore adjusted for multiple comparisons.
Fourth, previous VAS was not randomly allocated, it was
provided during national community campaigns. We cannot
exclude that receiving VAS in these campaigns was associated
with an unmeasured health-related factor, which may in fact be
the underlying effect modiﬁer of VAS. Nonetheless, of all the
recorded health-related factors, only age was associated with
previous VAS, and adjustment for age in the analysis did not
change the results.
Comparisons with other studies
Sex-differential effects of vitamin A supplementation. The
main trial found no overall effect of VAS on mortality, but
signiﬁcant interaction with sex. At the 6-month follow-up, VAS
increased the mortality risk in males (mortality rate ratio (MRR):
1·92; 95 % CI 0·98, 3·75) and reduced the risk in females (MRR:
0·45 (95 % CI 0·24, 0·87), interaction between VAS and
sex; P= 0·003)(15). In the present subgroup study, VAS had
sex-differential effects on leucocyte counts, being associated
with reduced counts in males and increased counts in females.
A few studies have investigated the effect of VAS on cell
counts, even less so have taken sex into account. In line with
the present ﬁndings, a previous study of VAS at birth in Guinea-
Bissau observed that VAS resulted in a higher frequency of
monocytes 6 weeks later, particularly in females, but with no
signiﬁcant effect in males(24). In contrast, another study from
Guinea-Bissau found no effect overall or by sex on lymphocyte
counts, percentages of CD4+ T cells, CD8+ T cells or the CD4:
CD8 T cell ratio 3 months after VAS v. placebo given with MV at
6 months of age(25).
Season-differential effects of vitamin A supplementation
The main trial found that the sex-differential effect of VAS was
strongest in the dry season(15). In the present sub-study, we
found no evidence for a season-differential effect of VAS overall
or by sex.
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Fig. 2. The effect of vitamin A supplementation (VAS) on leucocyte counts and in vitro cytokine responses. (a) Geometric mean ratios (GMR) of leucocyte counts
comparing VAS with placebo, stratified by sex. (b)–(f) GMR of in vitro cytokine responses comparing VAS with placebo, stratified by sex. (g) GMR for the effect of VAS
on ratios of phytohaemagglutinin (PHA) responses comparing VAS with placebo, stratified by previous VAS and sex. For TNF-α and IFN-γ responses of females with
no previous VAS, the VAS effect estimates are truncated at GMR= 0·125 for graphic reasons. Estimates were generated with linear regression for cytokines (b–g)
including multiple imputations to account for measurements below the detection level. For cytokines (b–g), if more than 50% of the measurements of a given cytokine
outcome was non-detectable, the estimate was obtained with Poisson regression, giving prevalence ratios. All estimates were adjusted for baseline levels. A GMR>1
can be interpreted as an increasing effect of VAS on the cell count. Estimates that are significant after adjustment for multiple comparisons: For VAS effect: * P< 0·05;
for interaction between VAS and sex: † P< 0·05; for interaction between VAS, sex and previous VAS: ‡‡‡ P< 0·001. Medium3, culture medium only in 3-d incubation;
poly I:C, polyinosine-polycytidylic acid; BCG, Bacille Calmette–Gúerin; PPD, purified protein derivative from Mycobacterium tuberculosis; OPV, oral polio vaccine,
TT, tetanus toxoid; DT, diphtheria toxoid; medium1, culture medium only in 1-d incubation; LPS, lipopolysaccharide; Pam, palmitoyl(3)-cysteine-serine-lysine(4).
, Male; , female.
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Fig. 3. The effect of vitamin A supplementation (VAS) on in vitro cytokine responses, stratified by previous VAS. Geometric mean ratios (GMR) of cytokine responses
to innate agonists and vaccine antigens (a–e) for VAS compared with placebo. If ≥50% of the measurements of a given cytokine outcome included in the analysis was
non-detectable (ND), the estimate was obtained with Poisson regression, giving prevalence ratios (PR). (f) The cytokine concentrations were analysed collectively
for all stimulations in a combined analysis for each cytokine, including all stimulations and adjusting for the main effect of stimulation. Panels (g, h) present GMR
ratios (GMRR) for the effect of VAS on ratios of responses of TNF-α:IL-10 and IFN-γ:IL-5, respectively. The analyses was only performed on distributions with <50%
ND measurements. ‘Group’ designates ratios of cytokine responses analysed collectively for all stimulations with <50% ND observations. All estimates were adjusted
for baseline level and sex. A GMR or GMRR (or PR)>1 can be interpreted as an increasing effect of VAS on the outcome. The estimates beyond the range of 0·25–4
were truncated: TNF-α to medium3, TNF-α to polyinosine-polycytidylic acid (Poly I:C), TNF-α to Poly I:C and TNF-α:IL-10 to Poly I:C in the no previous VAS stratum.
§ The cumulative estimate for the VAS effect on TNF-α responses in previous VAS recipients could not be generated, because the estimates for the respective
stimulations were too heterogeneous to be analysed collectively (test of homogeneity: P< 0·05). ‡ No estimate for the effect of VAS could be obtained for TNF-α to
diphtheria toxoid (DT), IL-2 to Poly I:C and IFN-γ to medium3, due to all observations being ND at follow-up among VAS recipients (TNF-α to DTand IFN-γ to medium3)
or placebo recipients (IL-2 to Poly I:C), respectively, not having previously received VAS. Estimates that are significant after adjustment for multiple comparisons:
* P< 0·05; for interaction between VAS and previous VAS: † P< 0·05; †† P< 0·01. Medium1, culture medium only in 1-d incubation; LPS, lipopolysaccharide; pam:
palmitoyl(3)-cysteine-serine-lysine(4); medium3, culture medium only in 3-d incubation; PHA, phytohaemagglutinin; poly I:C, polyinosine-polycytidylic acid;
BCG, Bacille Calmette–Gúerin; PPD, purified protein derivative from Mycobacterium tuberculosis; OPV, oral polio vaccine; TT, tetanus toxoid. , No previous VAS;
, previous VAS.
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Previous vitamin A supplementation modulating the effect
of vitamin A supplementation
The main trial found a strong interaction between VAS and
previous VAS. In previous VAS recipients, the MRR of VAS was
5·98 (1·34–26·7) in males and 0·18 (0·05–0·62) in females.
Among children not previously supplemented, the effects were
1·19 (0·53–2·65) in males and 0·82 (0·35–1·89) in females
(P = 0·007 for three-way interaction between VAS, previous
VAS and sex)(15). This corroborated observations from previous
studies of a particularly beneﬁcial effect of receiving repeated
doses of VAS in females(14,26).
In line with the mortality ﬁndings, in the present sub-study,
the immunological effect of VAS was modulated by previous
VAS, for some outcomes in a sex-differential manner. VAS
tended to increase the TNF-α:IL-10 ratios and IFN-γ:IL-5 ratios in
previous VAS recipients, with opposite effects in previously
unsupplemented children. To our knowledge, no other study
has investigated the immunological effect of repeated dosing
of VAS.
In an immunological study of the effect of MV at 4·5 months
of age, a large subgroup of children had previously received
VAS at birth. Exclusively among neonatal VAS recipients, MV
had sex-differential effects on plasma IL-1 receptor agonist and
IL-8. Furthermore, MV tended to increase the TNF-α:IL-10
response ratios among neonatal VAS recipients, with the
opposite effect of MV in previously unsupplemented infants(27).
These ﬁndings are in parallel with the present study, sup-
porting differential effects of immune-modulators (be it MV or
VAS) depending on previous VAS, with a dampening effect in
children who receive VAS for the ﬁrst time, but a larger
inﬂammatory response in children who have previously
received VAS.
The effect modulation of previous VAS on cytokine respon-
ses was furthermore sex dependent for the PHA stimulations,
most signiﬁcantly for IFN-γ. Of note, high IFN-γ responses
to PHA is a marker of improved survival in children(28,29).
Intriguingly, the immunological interactions for IFN-γ to PHA
were in line with the mortality ﬁndings for previously supple-
mented children(15).
Biological mechanisms
Using serum RBP as indicator of vitamin A stores, many children
in the present study had biochemical VAD, but VAS did not
seem to affect the prevalence of VAD. A previous study from
Guinea-Bissau examined the effect of VAS at birth on vitamin A
status at age 6 weeks and at age 4 months and also found no
measurable effect on vitamin A status(21), but in line with the
present trial there were, nonetheless, measureable effects on
mortality(13) and immunological outcomes(24). Of note, a bio-
logical model of vitamin A uptake and catabolism in children
has predicted a return of serum retinol levels to baseline only
2 months after high-dose VAS(30). These ﬁndings may suggest
that changes in vitamin A status measured as blood biochemical
markers do not serve as a good predictor of VAS effects on
mortality or on immune function. In other words, the effect of
VAS seems not to be mediated via an effect on vitamin A status,
but rather through immunomodulation. Other analyses such
as tissue examination may be more sensitive indicators of
vitamin A status than blood biomarkers. This, however, is not
feasible in population studies such as the present; in order to
categorise children as deﬁcient or not, serum biomarkers can
indeed be used(31).
Most immunological in vitro studies assign anti-inﬂammatory
capacities to retinoid acids, metabolites of vitamin A(32–36). Most
recently, it has been shown that pre-incubation of human
monocytes with all-trans retinoic acid (ATRA) reduces the
secondary inﬂammatory responses to innate agonist stimulation
in an ATRA dose-dependent manner. Moreover, ATRA suppressed
the increasing effect on BCG priming of monocytes in the
secondary responses. The suppressive effect of ATRA was
observed at the epigenetic level by an increase in suppressive
methylation markers at the IL-6 and TNF-α promoters, which
lasted at least 10 d in the in vitro model(37). The dampening
effect in vitro of vitamin A on cytokine responses is in
concordance with the present in vivo ﬁndings in children not
previously supplemented.
In conclusion, the present study supports that VAS has
immune-modulating effects and that the effects may depend on
the sex of the recipient. The immunological effects of VAS may
be modiﬁed by previous VAS, corroborating ﬁndings from
epidemiological studies indicating a long-lasting imprinting
effect of VAS on the immune system.
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